HEALTH
From Times Staff and Wire Reports
Glaxo Moves to Block Generic Zantac: The British pharmaceuticals company said it has taken legal action to block a Ciba-Geigy unit from marketing a cheap generic copy of its Zantac ulcer drug in the United States. The patent-infringement suit was filed in a New Jersey court against Geneva Pharmaceuticals Inc. Glaxo said Geneva’s plan to sell a generic Form 1 version of Zantac, beginning in 1996, would violate its patents on the newer Form 2, which has patent protection until 2002. Zantac is the world’s largest-selling prescription drug.
